A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy and a bladder-preserving combined modality treatment plan.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.
